Success Metrics

Clinical Success Rate
66.7%

Based on 24 completed trials

Completion Rate
67%(24/36)
Active Trials
132(64%)
Results Posted
100%(24 trials)
Terminated
12(6%)

Phase Distribution

Ph phase_3
16
8%
Ph early_phase_1
2
1%
Ph not_applicable
11
5%
Ph phase_1
85
41%
Ph phase_4
1
0%
Ph phase_2
86
42%

Phase Distribution

87

Early Stage

86

Mid Stage

17

Late Stage

Phase Distribution201 total trials
Early Phase 1First-in-human
2(1.0%)
Phase 1Safety & dosage
85(42.3%)
Phase 2Efficacy & side effects
86(42.8%)
Phase 3Large-scale testing
16(8.0%)
Phase 4Post-market surveillance
1(0.5%)
N/ANon-phased studies
11(5.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

55.8%

24 of 43 finished

Non-Completion Rate

44.2%

19 ended early

Currently Active

132

trials recruiting

Total Trials

205

all time

Status Distribution
Active(152)
Completed(24)
Terminated(19)
Other(10)

Detailed Status

Recruiting98
Active, not recruiting34
Completed24
Not yet recruiting20
Terminated12
Withdrawn7

Development Timeline

Analytics

Development Status

Total Trials
205
Active
132
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (1.0%)
Phase 185 (42.3%)
Phase 286 (42.8%)
Phase 316 (8.0%)
Phase 41 (0.5%)
N/A11 (5.5%)

Trials by Status

unknown42%
recruiting9848%
suspended63%
active_not_recruiting3417%
completed2412%
terminated126%
withdrawn73%
not_yet_recruiting2010%

Recent Activity

Clinical Trials (205)

Showing 20 of 205 trialsScroll for more
NCT07012044Phase 1

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Recruiting
NCT06317649Phase 2

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Recruiting
NCT06672146Phase 2

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Recruiting
NCT06034470Phase 1

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Active Not Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT06311227Phase 2

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting
NCT07468916Phase 2

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Not Yet Recruiting
NCT05828069Phase 2

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
NCT03739814Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recruiting
NCT06022939Phase 3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Recruiting
NCT06784726Phase 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recruiting
NCT05564390Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Recruiting
NCT07498465Phase 1

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

Withdrawn
NCT04293562Phase 3

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting
NCT02176967Phase 3

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Active Not Recruiting
NCT06724237Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Recruiting
NCT03959085Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Recruiting
NCT04994132Phase 3

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Active Not Recruiting
NCT05554406Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
205